TapewireFind a company

person · Reporting owner

Crane Rosemary A

Disclosed activity across 6 companies

Tapewire entity
40718
SEC CIK
0001443343

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Catalent, Inc.CTLT · Entity 16279DirectorOctober 27, 2023October 31, 2023
TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063DirectorJune 05, 2026June 08, 2026
Tarsus Pharmaceuticals, Inc.TARS · Entity 1836DirectorJune 24, 2024June 25, 2024
Unilife CorpUNIS · Entity 12414DirectorOctober 28, 2016November 07, 2016

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Catalent, Inc.

Report date October 27, 2023 · Filed October 31, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect23,873 Reported balance After 2023-10-27 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2023-10-27 · Grant · Acquired 6,993 · Balance 23,873

F1: The equity acquired by the reporting person is the annual grant of restricted stock units provided by the Issuer to the reporting person pursuant to the Issuer's non-employee director compensation program. Each restricted stock unit represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur one year from the date of award, subject to continued service.

F2: Includes restricted stock units.

Filing footnotes · ownership attribution and instrument terms

F1: The equity acquired by the reporting person is the annual grant of restricted stock units provided by the Issuer to the reporting person pursuant to the Issuer's non-employee director compensation program. Each restricted stock unit represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur one year from the date of award, subject to continued service.

F2: Includes restricted stock units.

TEVA PHARMACEUTICAL INDUSTRIES LTD

Report date June 05, 2026 · Filed June 08, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Ordinary SharesSEC Table I · non-derivativeDirect127,739 Reported balance After 2026-06-05 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-06-05 · Exercise / conversion · Acquired 14,492 · Balance 127,739

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Restricted Share UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2026-06-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-06-05 · Exercise / conversion · Disposed 14,492 · Balance 0

F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3: Restricted share units were granted on June 5, 2025 and vested on June 5, 2026.

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Filing footnotes · ownership attribution and instrument terms

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3: Restricted share units were granted on June 5, 2025 and vested on June 5, 2026.

Tarsus Pharmaceuticals, Inc.

Report date June 24, 2024 · Filed June 25, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect5,350 Reported balance After 2024-06-24 transaction · row 1
1 source row

Row 1 · 2024-06-24 · Exercise / conversion · Acquired 3,350 · Balance 5,350

F1: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2024-06-24 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2024-06-24 · Exercise / conversion · Disposed 3,350 · Balance 0

F2: Each RSU represents a contingent right to receive one share of the Company's common stock.

F3: RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

F2: Each RSU represents a contingent right to receive one share of the Company's common stock.

F3: RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

Unilife Corp

Report date October 28, 2016 · Filed November 07, 2016

This filing explicitly reported no securities owned.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Certara, Inc.

Report date May 14, 2026 · Filed May 15, 2026

Section 16 reporting ended · disclosed 2026-05-15. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect45,672 Reported balance After 2026-05-14 transaction · row 1
1 source row

Row 1 · 2026-05-14 · Exercise / conversion · Acquired 15,757 · Balance 45,672

F1: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2026-05-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-05-14 · Exercise / conversion · Disposed 15,757 · Balance 0

F1: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting.

PDS Biotechnology Corp

Report date March 15, 2019 · Filed March 18, 2019

Section 16 reporting ended · disclosed 2019-03-18. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect10,000 Reported balance After 2019-03-15 transaction · row 1
1 source row

Row 1 · 2019-03-15 · Exercise / conversion · Acquired 10,000 · Balance 10,000

F1: Vesting of RSUs granted to the Reporting Person on August 14, 2018.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2019-03-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2019-03-15 · Exercise / conversion · Disposed 10,000 · Balance 0

F2: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit.

F1: Vesting of RSUs granted to the Reporting Person on August 14, 2018.

F3: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria.

F4: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest.

Filing footnotes · ownership attribution and instrument terms

F1: Vesting of RSUs granted to the Reporting Person on August 14, 2018.

F2: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit.

F3: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria.

F4: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 05, 2026 Filed Jun 8, 2026 20:06 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 14,492 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-261706 · ownership.xml · derivative · entry 2

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 14,492 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on June 5, 2025 and vested on June 5, 2026.

F3 · derivative.expiration_date: Restricted share units were granted on June 5, 2025 and vested on June 5, 2026.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
June 05, 2026 Filed Jun 8, 2026 20:06 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 14,492 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-261706 · ownership.xml · nonDerivative · entry 1

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 127,739

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
May 28, 2026 Filed Jun 1, 2026 20:08 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 7,242 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-251416 · ownership.xml · derivative · entry 1

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,242

Underlying: Ordinary Shares · 7,242 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F2 · derivative.exercise_date: Restricted share units were granted on May 28, 2026 and vest on May 28, 2027.

F2 · derivative.expiration_date: Restricted share units were granted on May 28, 2026 and vest on May 28, 2027.

F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
May 14, 2026 Filed May 15, 2026 20:26 UTC Certara, Inc. CERT · Entity 787 Exercise / conversionRestricted Stock Units · Derivative 15,757 $0.00 $0.00
Disclosure

SEC source: 0001443343-26-000003 · form4-05152026_080506.xml · derivative · entry 2

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,757 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting.

F1 · derivative.exercise_date: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting.

F1 · derivative.expiration_date: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting.

Read SEC document
May 14, 2026 Filed May 15, 2026 20:26 UTC Certara, Inc. CERT · Entity 787 Exercise / conversionCommon Stock 15,757 $0.00 $0.00
Disclosure

SEC source: 0001443343-26-000003 · form4-05152026_080506.xml · nonDerivative · entry 1

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,672

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting.

Read SEC document
June 06, 2025 Filed Jun 9, 2025 20:09 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 9,632 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-083724 · ownership.xml · derivative · entry 2

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 9,632 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on June 6, 2024 and vested on June 6, 2025.

F3 · derivative.expiration_date: Restricted share units were granted on June 6, 2024 and vested on June 6, 2025.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
June 06, 2025 Filed Jun 9, 2025 20:09 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 9,632 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-083724 · ownership.xml · nonDerivative · entry 1

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 113,247

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
June 05, 2025 Filed Jun 9, 2025 20:09 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 14,492 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-083724 · ownership.xml · derivative · entry 3

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,492

Underlying: Ordinary Shares · 14,492 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F4 · derivative.exercise_date: Restricted share units were granted on June 5, 2025 and vest on June 5, 2026.

F4 · derivative.expiration_date: Restricted share units were granted on June 5, 2025 and vest on June 5, 2026.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
May 21, 2025 Filed May 22, 2025 21:03 UTC Certara, Inc. CERT · Entity 787 GrantRestricted Stock Units · Derivative 15,757 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-014190 · form4-05222025_090517.xml · derivative · entry 3

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,757

Underlying: Common Stock · 15,757 shares

Expires not disclosed

F2 · derivative.exercise_price: Each RSU was granted on May 21, 2025, under the 2020 Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting.

F2 · derivative.exercise_date: Each RSU was granted on May 21, 2025, under the 2020 Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting.

F2 · derivative.expiration_date: Each RSU was granted on May 21, 2025, under the 2020 Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting.

Read SEC document
May 21, 2025 Filed May 22, 2025 21:03 UTC Certara, Inc. CERT · Entity 787 Exercise / conversionRestricted Stock Units · Derivative 11,928 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-014190 · form4-05222025_090517.xml · derivative · entry 2

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,928 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") was granted on May 21, 2024, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 21, 2025, the day of the issuer's annual meeting.

F1 · derivative.exercise_date: Each restricted stock unit ("RSU") was granted on May 21, 2024, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 21, 2025, the day of the issuer's annual meeting.

F1 · derivative.expiration_date: Each restricted stock unit ("RSU") was granted on May 21, 2024, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 21, 2025, the day of the issuer's annual meeting.

Read SEC document
May 21, 2025 Filed May 22, 2025 21:03 UTC Certara, Inc. CERT · Entity 787 Exercise / conversionCommon Stock 11,928 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-014190 · form4-05222025_090517.xml · nonDerivative · entry 1

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,915

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") was granted on May 21, 2024, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 21, 2025, the day of the issuer's annual meeting.

Read SEC document
June 24, 2024 Filed Jun 25, 2024 22:26 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 Exercise / conversionRestricted Stock Units · Derivative 3,350 $0.00 $0.00
Disclosure

SEC source: 0001819790-24-000104 · wk-form4_1719354398.xml · derivative · entry 2

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,350 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock.

F3 · derivative.exercise_date: RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

F3 · derivative.expiration_date: RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

Read SEC document
June 24, 2024 Filed Jun 25, 2024 22:26 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 Exercise / conversionCommon Stock 3,350 Not disclosed Not disclosed
Disclosure

SEC source: 0001819790-24-000104 · wk-form4_1719354398.xml · nonDerivative · entry 1

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,350

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

Read SEC document
June 15, 2024 Filed Jun 17, 2024 11:41 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 21,108 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-074022 · ownership.xml · derivative · entry 2

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 21,108 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted Share Units were granted on June 15, 2023 and vested on June 15, 2024.

F3 · derivative.expiration_date: Restricted Share Units were granted on June 15, 2023 and vested on June 15, 2024.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
June 15, 2024 Filed Jun 17, 2024 11:41 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 21,108 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-074022 · ownership.xml · nonDerivative · entry 1

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 103,615

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
June 13, 2024 Filed Jun 14, 2024 21:40 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 GrantRestricted Stock Units · Derivative 3,350 $0.00 $0.00
Disclosure

SEC source: 0001819790-24-000081 · wk-form4_1718401236.xml · derivative · entry 2

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,350

Underlying: Common Stock · 3,350 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

F3 · derivative.exercise_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

F3 · derivative.expiration_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

Read SEC document
June 13, 2024 Filed Jun 14, 2024 21:40 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 GrantStock Option (right to buy) · Derivative 5,000 $0.00 Strike: $33.14 $0.00
Disclosure

SEC source: 0001819790-24-000081 · wk-form4_1718401236.xml · derivative · entry 1

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2034-06-12

F1 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

Read SEC document
June 06, 2024 Filed Jun 10, 2024 11:49 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 9,632 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-071076 · ownership.xml · derivative · entry 1

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,632

Underlying: Ordinary Shares · 9,632 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F2 · derivative.exercise_date: Restricted share units were granted on June 6, 2024 and vest on June 6, 2025.

F2 · derivative.expiration_date: Restricted share units were granted on June 6, 2024 and vest on June 6, 2025.

F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
May 21, 2024 Filed May 23, 2024 20:35 UTC Certara, Inc. CERT · Entity 787 GrantRestricted Stock Units · Derivative 11,928 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-014283 · form4-05232024_080513.xml · derivative · entry 3

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,928

Underlying: Common Stock · 11,928 shares

Expires not disclosed

F2 · derivative.exercise_price: Each RSU was granted on May 21, 2024, under the Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting.

F2 · derivative.exercise_date: Each RSU was granted on May 21, 2024, under the Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting.

F2 · derivative.expiration_date: Each RSU was granted on May 21, 2024, under the Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting.

Read SEC document
May 21, 2024 Filed May 23, 2024 20:35 UTC Certara, Inc. CERT · Entity 787 Exercise / conversionRestricted Stock Units · Derivative 8,663 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-014283 · form4-05232024_080513.xml · derivative · entry 2

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,663 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") was granted on May 23, 2023, under Certara, Inc.'s 2020 Incentive Plan ("Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 21, 2024, the day of the issuer's annual meeting.

F1 · derivative.exercise_date: Each restricted stock unit ("RSU") was granted on May 23, 2023, under Certara, Inc.'s 2020 Incentive Plan ("Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 21, 2024, the day of the issuer's annual meeting.

F1 · derivative.expiration_date: Each restricted stock unit ("RSU") was granted on May 23, 2023, under Certara, Inc.'s 2020 Incentive Plan ("Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 21, 2024, the day of the issuer's annual meeting.

Read SEC document
May 21, 2024 Filed May 23, 2024 20:35 UTC Certara, Inc. CERT · Entity 787 Exercise / conversionCommon Stock 8,663 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-014283 · form4-05232024_080513.xml · nonDerivative · entry 1

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,987

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") was granted on May 23, 2023, under Certara, Inc.'s 2020 Incentive Plan ("Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 21, 2024, the day of the issuer's annual meeting.

Read SEC document
October 27, 2023 Filed Oct 31, 2023 21:02 UTC Catalent, Inc. CTLT · Entity 16279 GrantCommon Stock 6,993 $0.00 $0.00
Disclosure

SEC source: 0001596783-23-000155 · wk-form4_1698786117.xml · nonDerivative · entry 1

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,873

F1 · shares: The equity acquired by the reporting person is the annual grant of restricted stock units provided by the Issuer to the reporting person pursuant to the Issuer's non-employee director compensation program. Each restricted stock unit represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur one year from the date of award, subject to continued service.

F2 · balance_after: Includes restricted stock units.

Read SEC document
August 04, 2023 Filed Aug 7, 2023 20:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 15,810 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-044772 · doc4.xml · derivative · entry 2

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 15,810 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on August 4, 2022 and vested on August 4, 2023.

F3 · derivative.expiration_date: Restricted share units were granted on August 4, 2022 and vested on August 4, 2023.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
August 04, 2023 Filed Aug 7, 2023 20:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 15,810 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-044772 · doc4.xml · nonDerivative · entry 1

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,507

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
June 22, 2023 Filed Jun 26, 2023 22:10 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 GrantRestricted Stock Units · Derivative 3,350 $0.00 $0.00
Disclosure

SEC source: 0001819790-23-000062 · wk-form4_1687817414.xml · derivative · entry 2

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,350

Underlying: Common Stock · 3,350 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

F3 · derivative.exercise_date: RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

F3 · derivative.expiration_date: RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

Read SEC document
June 22, 2023 Filed Jun 26, 2023 22:10 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 GrantStock Option (right to buy) · Derivative 5,000 $0.00 Strike: $17.99 $0.00
Disclosure

SEC source: 0001819790-23-000062 · wk-form4_1687817414.xml · derivative · entry 1

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2033-06-21

F1 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

Read SEC document
June 16, 2023 Filed Jun 21, 2023 22:27 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 Exercise / conversionRestricted Stock Units · Derivative 2,000 $0.00 $0.00
Disclosure

SEC source: 0001819790-23-000046 · wk-form4_1687386442.xml · derivative · entry 2

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock.

F3 · derivative.exercise_date: RSUs granted on June 16, 2022, in connection with the Reporting Person's service as a non-employee director as of the Company's 2022 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

F3 · derivative.expiration_date: RSUs granted on June 16, 2022, in connection with the Reporting Person's service as a non-employee director as of the Company's 2022 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

Read SEC document
June 16, 2023 Filed Jun 21, 2023 22:27 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 Exercise / conversionCommon Stock 2,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001819790-23-000046 · wk-form4_1687386442.xml · nonDerivative · entry 1

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

Read SEC document
June 15, 2023 Filed Jun 20, 2023 11:32 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 21,108 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-038218 · doc4.xml · derivative · entry 1

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,108

Underlying: Ordinary Shares · 21,108 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F2 · derivative.exercise_date: Restricted share units were granted on June 15, 2023 and vest on June 15, 2024.

F2 · derivative.expiration_date: Restricted share units were granted on June 15, 2023 and vest on June 15, 2024.

F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
May 23, 2023 Filed May 25, 2023 12:45 UTC Certara, Inc. CERT · Entity 787 GrantRestricted Stock Units · Derivative 8,663 $0.00 $0.00
Disclosure

SEC source: 0001415889-23-008750 · form4-05252023_120547.xml · derivative · entry 3

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,663

Underlying: Common Stock · 8,663 shares

Expires not disclosed

F2 · derivative.exercise_price: Represents RSUs granted on May 23, 2023, under the 2020 Incentive Plan that entitles the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual shareholder meeting.

F2 · derivative.exercise_date: Represents RSUs granted on May 23, 2023, under the 2020 Incentive Plan that entitles the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual shareholder meeting.

F2 · derivative.expiration_date: Represents RSUs granted on May 23, 2023, under the 2020 Incentive Plan that entitles the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual shareholder meeting.

Read SEC document
May 23, 2023 Filed May 25, 2023 12:45 UTC Certara, Inc. CERT · Entity 787 Exercise / conversionRestricted Stock Units · Derivative 9,324 $0.00 $0.00
Disclosure

SEC source: 0001415889-23-008750 · form4-05252023_120547.xml · derivative · entry 2

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,324 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents restricted stock units ("RSUs") granted on July 21, 2022, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") that entitles the reporting person to receive one share of the Issuer's common stock per RSU. The RSUs vested and were converted into common shares on the day of the annual meeting of the Issuer.

F1 · derivative.exercise_date: Represents restricted stock units ("RSUs") granted on July 21, 2022, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") that entitles the reporting person to receive one share of the Issuer's common stock per RSU. The RSUs vested and were converted into common shares on the day of the annual meeting of the Issuer.

F1 · derivative.expiration_date: Represents restricted stock units ("RSUs") granted on July 21, 2022, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") that entitles the reporting person to receive one share of the Issuer's common stock per RSU. The RSUs vested and were converted into common shares on the day of the annual meeting of the Issuer.

Read SEC document
May 23, 2023 Filed May 25, 2023 12:45 UTC Certara, Inc. CERT · Entity 787 Exercise / conversionCommon Stock 9,324 $0.00 $0.00
Disclosure

SEC source: 0001415889-23-008750 · form4-05252023_120547.xml · nonDerivative · entry 1

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,324

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Represents restricted stock units ("RSUs") granted on July 21, 2022, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") that entitles the reporting person to receive one share of the Issuer's common stock per RSU. The RSUs vested and were converted into common shares on the day of the annual meeting of the Issuer.

Read SEC document
October 27, 2022 Filed Oct 31, 2022 20:46 UTC Catalent, Inc. CTLT · Entity 16279 GrantCommon Stock 4,149 $0.00 $0.00
Disclosure

SEC source: 0001596783-22-000167 · wf-form4_166724918637731.xml · nonDerivative · entry 1

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,880

F1 · kind: The equity acquired by the reporting person is the regular, annual grant of restricted stock units provided by the Issuer to the reporting person pursuant to the Issuer's non-employee director compensation package. Each restricted stock unit represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur on the earlier of one year from the date of award and the date of the Issuer's fiscal 2023 annual meeting of shareholders.

F2 · balance_after: Includes restricted stock units.

Read SEC document
August 04, 2022 Filed Aug 8, 2022 11:13 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 15,810 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-044690 · doc4.xml · derivative · entry 1

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,810

Underlying: Ordinary Shares · 15,810 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F2 · derivative.exercise_date: Restricted share units were granted on August 4, 2022 and vest on August 4, 2023.

F2 · derivative.expiration_date: Restricted share units were granted on August 4, 2022 and vest on August 4, 2023.

F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
July 21, 2022 Filed Jul 22, 2022 20:36 UTC Certara, Inc. CERT · Entity 787 GrantRestricted Stock Units · Derivative 9,324 $0.00 $0.00
Disclosure

SEC source: 0001415889-22-007919 · form4-07222022_010703.xml · derivative · entry 1

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,324

Underlying: Common Stock · 9,324 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock.

F2 · shares: Represents 9,324 RSUs granted under the Certara Inc. 2020 Incentive Plan that will entitle the reporting person to receive one share of the Issuer's Common Stock per RSU. The RSUs will vest on the earlier of the one-year anniversary of the date of grant or the date of the Issuer's next annual shareholder meeting.

F3 · derivative.exercise_date: The RSUs will vest on the earlier of the one-year anniversary of the date of grant or the date of the Issuer's next annual shareholder meeting.

F3 · derivative.expiration_date: The RSUs will vest on the earlier of the one-year anniversary of the date of grant or the date of the Issuer's next annual shareholder meeting.

Read SEC document
June 16, 2022 Filed Jul 1, 2022 16:18 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 GrantRestricted Stock Units · Derivative 2,000 $0.00 $0.00
Disclosure

SEC source: 0001628280-22-018341 · wf-form4_165669232112399.xml · derivative · entry 2

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000

Underlying: Common Stock · 2,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

F3 · derivative.exercise_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2022 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

F3 · derivative.expiration_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2022 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

Read SEC document
June 16, 2022 Filed Jul 1, 2022 16:18 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 GrantStock Option (right to buy) · Derivative 7,000 $0.00 Strike: $12.89 $0.00
Disclosure

SEC source: 0001628280-22-018341 · wf-form4_165669232112399.xml · derivative · entry 1

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,000

Underlying: Common Stock · 7,000 shares

Expires 2032-06-15

F1 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2022 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

Read SEC document
June 14, 2022 Filed Jun 16, 2022 11:33 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 14,479 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-037245 · doc4.xml · derivative · entry 2

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 14,479 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on June 14, 2021 and vested on June 14, 2022.

F3 · derivative.expiration_date: Restricted share units were granted on June 14, 2021 and vested on June 14, 2022.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
June 14, 2022 Filed Jun 16, 2022 11:33 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 14,479 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-037245 · doc4.xml · nonDerivative · entry 1

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,697

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
October 28, 2021 Filed Nov 1, 2021 12:00 UTC Catalent, Inc. CTLT · Entity 16279 GrantCommon Stock 1,402 $0.00 $0.00
Disclosure

SEC source: 0001596783-21-000171 · wf-form4_163576799959909.xml · nonDerivative · entry 1

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,731

F1 · kind: The equity acquired by the reporting person is the regular, annual grant of restricted stock units provided by the Issuer to the reporting person pursuant to the Issuer's non-management director compensation package. Each restricted stock unit represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur on the earlier of one year from the date of award and the date of the Issuer's fiscal 2022 annual meeting of shareholders.

F2 · balance_after: Includes restricted stock units.

Read SEC document
August 11, 2021 Filed Aug 12, 2021 23:28 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 GrantStock Option (right to buy) · Derivative 20,000 $0.00 Strike: $25.05 $0.00
Disclosure

SEC source: 0001209191-21-051272 · doc4.xml · derivative · entry 1

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2031-08-11

F1 · derivative.exercise_date: The option shares vest in 3 annual installments beginning on August 11, 2022, subject to the Reporting Person's continuous service.

Read SEC document
June 14, 2021 Filed Jun 16, 2021 12:12 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 14,479 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-040806 · doc4.xml · derivative · entry 1

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,479

Underlying: Ordinary Shares · 14,479 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F2 · derivative.exercise_date: Restricted share units were granted on June 14, 2021 and vest on June 14, 2022.

F2 · derivative.expiration_date: Restricted share units were granted on June 14, 2021 and vest on June 14, 2022.

F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
June 09, 2021 Filed Jun 10, 2021 11:39 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 12,668 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-039368 · doc4.xml · derivative · entry 2

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 12,668 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on June 9, 2020 and vested on June 9, 2021.

F3 · derivative.expiration_date: Restricted share units were granted on June 9, 2020 and vested on June 9, 2021.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
June 09, 2021 Filed Jun 10, 2021 11:39 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 12,668 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-039368 · doc4.xml · nonDerivative · entry 1

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,218

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
June 05, 2021 Filed Jun 8, 2021 12:19 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 6,041 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-038820 · doc4.xml · derivative · entry 2

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 6,041 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on June 5, 2018 and vested on June 5, 2021.

F3 · derivative.expiration_date: Restricted share units were granted on June 5, 2018 and vested on June 5, 2021.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
June 05, 2021 Filed Jun 8, 2021 12:19 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 6,041 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-038820 · doc4.xml · nonDerivative · entry 1

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,550

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
October 29, 2020 Filed Nov 2, 2020 12:21 UTC Catalent, Inc. CTLT · Entity 16279 GrantCommon Stock 2,125 $0.00 $0.00
Disclosure

SEC source: 0001596783-20-000212 · wf-form4_160431963231686.xml · nonDerivative · entry 1

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,329

F1 · kind: The equity acquired by the reporting person is the regular, annual grant of restricted stock units provided by the Issuer to the reporting person pursuant to the Issuer's non-management director compensation package. Each restricted stock unit represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur on the earlier of one year from the date of award and the date of the Issuer's fiscal 2021 annual meeting of shareholders.

F2 · balance_after: Includes restricted stock units.

Read SEC document
August 27, 2020 Filed Aug 28, 2020 22:46 UTC Catalent, Inc. CTLT · Entity 16279 GrantCommon Stock 661 $0.00 $0.00
Disclosure

SEC source: 0001596783-20-000142 · wf-form4_159865478139855.xml · nonDerivative · entry 1

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,204

F1 · kind: The equity acquired by the reporting person is part of the regular, annual grant of restricted stock units provided by the Issuer to the reporting person pursuant to the Issuer's non-management director compensation package. The grant is in respect of the period between July 1, 2020 and the date of the reporting person's annual meeting of shareholders in respect of fiscal 2020. Each restricted stock unit represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur one year from the date of award.

F2 · balance_after: Includes restricted stock units.

Read SEC document
August 11, 2020 Filed Aug 13, 2020 20:07 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 7,956 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-046581 · doc4.xml · derivative · entry 3

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 7,956 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5 · derivative.exercise_date: Restricted share units were granted on August 11, 2017 and vested on August 11, 2020.

F5 · derivative.expiration_date: Restricted share units were granted on August 11, 2017 and vested on August 11, 2020.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
August 11, 2020 Filed Aug 13, 2020 20:07 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 2,860 $11.90 $34,037.72
Disclosure

SEC source: 0001209191-20-046581 · doc4.xml · nonDerivative · entry 2

Crane Rosemary A · CIK 0001443343 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,509

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.9000 to $11.9050, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.